文献速递湿疹皮炎与荨麻疹

口服益生菌混合物对中度特应性皮炎患儿SCORAD指数及外用激素使用的影响:一项随机临床试验

Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2018-01-01

该12周随机双盲安慰剂对照试验纳入50例4-17岁中度特应性皮炎患儿,评估口服益生菌混合物(Bifidobacterium lactis CECT 8145、B longum CECT 7347和Lactobacillus casei CECT 9104)的疗效。结果显示益生菌组SCORAD指数平均降幅较对照组多19.2分,且外用激素使用天数显著减少。

要点

  • 益生菌组SCORAD指数相对变化为-83%,显著优于安慰剂组的-24%。
  • 益生菌组外用激素使用天数为7.7%,低于对照组的10.8%。
  • 口服益生菌混合物可安全有效地改善中度特应性皮炎症状。

核心结论

  • 益生菌混合物能有效降低中度特应性皮炎患儿的SCORAD指数并减少外用激素使用。

研究设计与样本

  • 12周随机双盲安慰剂对照干预试验,2016年3月至6月在西班牙阿利坎特门诊进行,纳入50例4-17岁中度特应性皮炎患儿。

主要发现

  • 益生菌组SCORAD指数平均降幅较对照组多19.2分(均值差-19.2;95%CI -15.0至-23.4)。
  • 益生菌组SCORAD相对变化为-83%(95%CI -95%至-70%),安慰剂组为-24%(95%CI -36%至-11%),P<.001。
  • 益生菌组外用激素使用天数为2084患者日中的161日(7.7%),对照组为2032患者日中的220日(10.8%),比值比0.63(95%CI 0.51至0.78)。

关键数值与推荐

  • 干预为每日胶囊含10^9总菌落形成单位的Bifidobacterium lactis CECT 8145、B longum CECT 7347和Lactobacillus casei CECT 9104及麦芽糊精载体,持续12周。
  • 主要结局为SCORAD指数评分和外用激素使用天数。

临床怎么用

  • 对于4-17岁中度特应性皮炎患儿,可考虑口服特定益生菌混合物作为辅助治疗以减少SCORAD指数和外用激素用量。

局限性

  • 样本量较小(50例),研究时间为2016年3月至6月,结论需在更大样本和更广人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Oral intake of new probiotic formulations may improve the course of atopic dermatitis (AD) in a young population. OBJECTIVE: To determine whether a mixture of oral probiotics is safe and effective in the treatment of AD symptoms and to evaluate its influence on the use of topical steroids in a young population. DESIGN, SETTING, AND PARTICIPANTS: A 12-week randomized, double-blind, placebo-controlled intervention trial, from March to June 2016, at the outpatient hospital Centro Dermatológico Estético de Alicante, Alicante, Spain. Observers were blinded to patient groupings. Participants were children aged 4 to 17 years with moderate atopic dermatitis. The groups were stratified and block randomized according to sex, age, and age of onset. Patients were ineligible if they had used systemic immunosuppressive drugs in the previous 3 months or antibiotics in the previous 2 weeks or had a concomitant diagnosis of intestinal bowel disease or signs of bacterial infection. INTERVENTIONS: Twelve weeks with a daily capsule containing freeze-dried powder with 109 total colony-forming units of the probiotic strains Bifidobacterium lactis CECT 8145, B longum CECT 7347, and Lactobacillus casei CECT 9104 and maltodextrin as a carrier, or placebo (maltodextrin-only capsules). MAIN OUTCOMES AND MEASURES: SCORAD index score and days of topical steroid use were analyzed. RESULTS: Fifty children (26 [50%] female; mean [SD] age, 9.2 [3.7] years) participated. After 12 weeks of follow-up, the mean reduction in the SCORAD index in the probiotic group was 19.2 points greater than in the control group (mean difference, -19.2; 95% CI, -15.0 to -23.4). In relative terms, we observed a change of -83% (95% CI, -95% to -70%) in the probiotic group and -24% (95% CI, -36% to -11%) in the placebo group (P < .001). We found a significant reduction in the use of topical steroids to treat flares in the probiotic arm (161 of 2084 patient-days [7.7%]) compared with the control arm (220 of 2032 patient-days [10.8%]; odds ratio, 0.63; 95% CI, 0.51 to 0.78). CONCLUSIONS AND RELEVANCE: The mixture of probiotics was effective in reducing SCORAD index and reducing the use of topical steroids in patients with moderate AD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02585986.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Navarro-López V, Ramírez-Boscá A, Ramón-Vidal D, et al. Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2018. PMID: 29117309. doi:10.1001/jamadermatol.2017.3647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。